Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Pertuzumab Biosimilar - Anti-ERBB2/EGFR2/CD340 mAb - Research Grade |
---|---|
Source | CAS 380610-27-5 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | OMNITARG,rhuMAB 2C4 |
Reference | PX-TA1058-SIL |
Related Products | PX-P3061 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of human epidermal growth factor receptor 2 protein (HER2). It was first used with docetaxel and another HER2-targeting monoclonal antibody trastuzumab to treat metastatic HER2-positive breast cancer. Since then, its indications have been expanded to be used as both neoadjuvant therapy and adjuvant therapy for the treatment of HER2-positive breast cancer with a high risk of recurrence.
Reviews
Il n’y a pas encore d’avis.